Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC

NCT03689855 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer
Non Small Cell Lung Cancer
NSCLC

Interventions

DRUG: Ramucirumab
DRUG: Atezolizumab
PROCEDURE: Peripheral blood draw
PROCEDURE: Biopsy

Sponsor

Washington University School of Medicine

Collaborators

[object Object]